×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Fresh Tracks, Histogen to Shutter Businesses in Absence of Viable Options
BioSpace
The companies have announced the impending closures of their respective businesses. Histogen will lay off most of its employees by the end...
8 months ago
Deal focus: Fresh Tracks discloses its $8.25m buyout from Botanix
Clinical Trials Arena
Fresh Tracks will sell its rights to forthcoming event-based milestones and profits on net sales of sofpironium bromide to Botanix SB.
10 months ago
Basilea anti-infective strategy restarts with $2M antifungal buy
Fierce Biotech
Basilea Pharmaceutica is hoping to have better luck with its second attempt to build out its anti-infective pipeline.
7 months ago
Cash-strapped Fresh Tracks pauses R&D run as search for a buyer continues
Fierce Biotech
Fresh Tracks Therapeutics has revealed that R&D work was paused in the second quarter to hold onto more cash while it mulls "strategic...
9 months ago
Brickell Biotech to rebrand as Fresh Tracks Therapeutics
Medical Marketing and Media
Brickell Biotech to rebrand as Fresh Tracks Therapeutics. The Colorado-based company's stock will begin trading under a new Nasdaq ticker symbol...
20 months ago
Korea’s bio startup Voronoi inks $324 million deal with Brickell Biotech
KED Global
Voronoi Inc., a South Korean biotechnology startup, has clinched a $324 million deal to grant Brickell Biotech, a US clinical-stage...
32 months ago
BBI stock on watch as company changes name to Fresh Tracks Therapeutics (NASDAQ:BBI)
Seeking Alpha
Clinical-stage biotech Brickell Biotech, Inc. (BBI) announced a major rebranding exercise on Wednesday, renaming its corporate identity to...
20 months ago
Brickell Biotech receives delisting notice from Nasdaq
Colorado Daily
Brickell Biotech Inc. received notice from the stock market Tuesday that it faces delisting for remaining in violation of the bid price rule...
23 months ago
Vical and Brickell Announce Merger Agreement
GlobeNewswire
Combined Company Well-Capitalized with Approximately $35 Million in Cash and up to $25 Million in Near-Term R&D FundingPivotal Phase 3...
59 months ago
Boulder biotech firm enters reverse merger valued at up to $60 million - Denver Business Journal
The Business Journals
In addition to capital, the Boulder company also gains a listing on the Nasdaq.
59 months ago